ArticleScientific reports2025
Metabolomic and clinical feature analyses of plasma from influenza A patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structure-Based Comparative Metabolomics Identifies LysoPE 15:0 as a Candidate Metabolite Marker of Influenza Virus Infection Dynamics.Molecules (Basel, Switzerland) · 2026Article
- Bovine Parainfluenza Virus Type 3 Infection Reprograms the Bovine Serum Lipidome Associated with Phosphatidylinositol Depletion and Sphingolipid Axis Activation.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Plasma metabolomics offers valuable insights for identifying viral infection biomarkers with applications in early diagnosis, outcome prediction, and treatment monitoring. This study aimed to investigate metabolomic alterations in influenza A patients and identify potential biomarkers for disease severity. From March 2023 to March 2024, 339 influenza A patients were enrolled. After age‒sex matching, 54 patients and 20 healthy controls were selected for analysis. Untargeted metabolomic profiling of 74 plasma samples was conducted using ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry. Comparative analysis revealed 60 differentially expressed metabolites between H1N1 patients and healthy controls, with 41 significantly upregulated and 19 downregulated. Pathway enrichment analysis revealed prominent disruptions in glycerophospholipid metabolism, with several metabolites showing alterations across the severity spectrum. Amino acid metabolism, particularly propionate metabolism, glycine-serine-threonine metabolism, and branched-chain amino acid biosynthesis, was also notably disturbed. Critical exhibited marked disturbances in taurine-hypotaurine metabolism compared to milder. This study identified glycerophospholipid metabolism dysregulation as a potential biomarker for influenza severity stratification. The progressive alteration of taurine pathway metabolites in critical suggests their pivotal role in severe H1N1 pathogenesis, highlighting their dual potential as diagnostic biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.